Issues
Risk has been rising for a while, and this week, we’ve seen some wild action along with some abnormal selling. That said, we haven’t seen a rash of breakdowns, either, so we’re moving gradually--we pared back some earlier this week, leaving us with 27% in cash, but we’re also willing to give our stocks a bit of rope as we wait to see how this plays out. As always, we’re flexible when looking ahead, and are willing to put money to work if this morphs into yet another shakeout, or pare back further if the sellers stay at it.
In tonight’s issue, we go over all our stocks in depth, write a piece about the marijuana industry and talk about a couple of intriguing individual stocks that have been setting up for months and could be ready to go if the market can find support.
In tonight’s issue, we go over all our stocks in depth, write a piece about the marijuana industry and talk about a couple of intriguing individual stocks that have been setting up for months and could be ready to go if the market can find support.
2021 kicked off with a bang, as investors small and large poured money into marijuana stocks in anticipation of growing legalization, so our portfolio is off to a fine start.
But the threat of a downturn is ever-present, and the longer the bull market runs, the greater my unease.
Still, I can’t argue with the trend, which by all measurements remains up, so I’m keeping the portfolio fully invested. And if you’ve got cash, the softness of recent days is now presenting some buying opportunities!Full details in the issue.
Full details in the issue.
But the threat of a downturn is ever-present, and the longer the bull market runs, the greater my unease.
Still, I can’t argue with the trend, which by all measurements remains up, so I’m keeping the portfolio fully invested. And if you’ve got cash, the softness of recent days is now presenting some buying opportunities!Full details in the issue.
Full details in the issue.
The S&P 500 is making yet another new all time high. The index has risen 72% since last March and over 17% just since the beginning of October. That’s amazing performance in a short amount of time.
I’m positive on the market for the rest of this year as a full recovery along with low interest rates and massive stimulus should be very positive for stocks. But the market never goes straight up. And a selloff is overdue. It would present a buying opportunity ahead of a promising year.
While I am increasingly cautious in the near term, there are very select places where great value can still be found. And even fewer that historically move independently of the overall market.
In this issue I highlight a stock that moves to its own drummer and not with the market. It is near the low point of its range in a long-term uptrend facilitated by rapid growth in its business. The situation presents an ideal time to buy into the stock now and write calls later.
I’m positive on the market for the rest of this year as a full recovery along with low interest rates and massive stimulus should be very positive for stocks. But the market never goes straight up. And a selloff is overdue. It would present a buying opportunity ahead of a promising year.
While I am increasingly cautious in the near term, there are very select places where great value can still be found. And even fewer that historically move independently of the overall market.
In this issue I highlight a stock that moves to its own drummer and not with the market. It is near the low point of its range in a long-term uptrend facilitated by rapid growth in its business. The situation presents an ideal time to buy into the stock now and write calls later.
Thank you for subscribing to the Cabot Turnaround Letter. We hope you enjoy reading the February 2021 issue.
This month we look at energy pipeline stocks. These companies are heavily out of favor, yet a secular shift in their strategic priorities may finally restore their appeal. We list five that look attractive.
We also explore some bargains in the United Kingdom. This island nation is dually challenged by Brexit and the pandemic. We highlight seven stocks that have company-specific turnarounds that look promising.
Our feature recommendation is Viatris (VTRS). Created through the recent merger of Mylan and Pfizer’s Upjohn division, this company is now one of the world’s largest generic pharmaceutical manufacturers. Viatris should generate stable revenues and solid free cash flow, but investor skepticism is high. With the shares trading at a low 4.3x earnings, the step-up in leadership quality and transparency, and an attractive 5.2% dividend yield, the shares look poised for considerable gains.
We also include comments on recent price target and ratings changes, including our earlier sell recommendation on DuPont.
Please feel free to send me your questions and comments. This newsletter is written for you. A great way to get more out of your letter is to let me know what you are looking for.
I’m best reachable at Bruce@CabotWealth.com. I’ll do my best to respond as quickly as possible.
This month we look at energy pipeline stocks. These companies are heavily out of favor, yet a secular shift in their strategic priorities may finally restore their appeal. We list five that look attractive.
We also explore some bargains in the United Kingdom. This island nation is dually challenged by Brexit and the pandemic. We highlight seven stocks that have company-specific turnarounds that look promising.
Our feature recommendation is Viatris (VTRS). Created through the recent merger of Mylan and Pfizer’s Upjohn division, this company is now one of the world’s largest generic pharmaceutical manufacturers. Viatris should generate stable revenues and solid free cash flow, but investor skepticism is high. With the shares trading at a low 4.3x earnings, the step-up in leadership quality and transparency, and an attractive 5.2% dividend yield, the shares look poised for considerable gains.
We also include comments on recent price target and ratings changes, including our earlier sell recommendation on DuPont.
Please feel free to send me your questions and comments. This newsletter is written for you. A great way to get more out of your letter is to let me know what you are looking for.
I’m best reachable at Bruce@CabotWealth.com. I’ll do my best to respond as quickly as possible.
The stock market has been swinging up and down in recent days as investors digest fourth-quarter earnings results and look for the next catalyst to move markets. That said, it’s a good idea to get a bit more defensive with new positions, focusing on established stocks that are less volatile.
The market’s main trend remains up, and thus I continue to recommend that you be heavily invested.
At the same time, it’s important (as ever) to monitor your individual stocks and prune any from your portfolio that no longer deserve to be there. In our portfolio, there are no stocks that fall into that category this week.
But the market is pricey. Stocks are extended. So today’s recommendation is a low-risk dividend-payer with solid growth prospects as the world transitions to a world of clean energy.
Details inside.
At the same time, it’s important (as ever) to monitor your individual stocks and prune any from your portfolio that no longer deserve to be there. In our portfolio, there are no stocks that fall into that category this week.
But the market is pricey. Stocks are extended. So today’s recommendation is a low-risk dividend-payer with solid growth prospects as the world transitions to a world of clean energy.
Details inside.
Current Market OutlookIt’s usually hardest to keep things simplest, which is why we put our main emphasis on the trends of the major indexes and action of leading stocks—and with both of those still positive, we’re sticking to a generally bullish stance. However, there’s little doubt we’re seeing some late-in-the-advance happenings (heavily-shorted stocks going to the moon, wild rotation intraday among sectors, etc.) and, chart-wise, nearly everything is sticking straight up in the air (the Nasdaq was about 1,100 points above its 50-day line this morning). We never pick tops, but we also prefer not to leave our brains at the door, and there’s little doubt that the risk/reward for most stocks here isn’t great. Thus, we’re willing to give things some wiggle room, but we’re raising stops and being selective on the buy side, focused mostly on entering on dips.
This week’s list has a wide mix of stocks, and most have been either setting up during the past few months or staging initial pullbacks after huge runs. Our Top Pick is Cleveland-Cliffs (CLF), which is finally beginning to pull in after a big run—further dips would be tempting.
| Stock Name | Price | ||
|---|---|---|---|
| 10X Genomics (TXG) | 183 | ||
| 1Life Healthcare (ONEM) | 51 | ||
| Cleveland-Cliffs (CLF) | 17 | ||
| Cronos Group (CRON) | 10 | ||
| Goldman Sachs Group, Inc. (GS) | 283 | ||
| Inseego (INSG) | 21 | ||
| Peloton (PTON) | 157 | ||
| Schrodinger, Inc. (SDGR) | 96 | ||
| Shopify (SHOP) | 1206 | ||
| Unity Software (U) | 151 |
Get this Investor Briefing now, Everything You Need to Know about Ground-Floor Opportunities, and you’ll learn about investing opportunities that can make you a fortune because you’re in at the beginning. From the secrets to early-stage stock profits to how to find big-performing small-cap stocks … from beer stocks with big potential to the best investing strategy in a down market … and from hottest IPOs to MedTech stocks with huge upside. Everything You Need to Know about Ground-Floor Opportunities is your best guide to knowing where and when to invest in the newest companies.
2021 is off to a good start thanks to strong earnings and continued investor enthusiasm for big technology companies and a new administration. The backstop from governments and central banks, as well as the consensus among investors that a strong economic recovery is coming this year, has for now pushed volatility out of the market.
The Explorer portfolio had a good week and today we add another SPAC merging with an established, fast-growing financial payments firm based in the United Kingdom.
The Explorer portfolio had a good week and today we add another SPAC merging with an established, fast-growing financial payments firm based in the United Kingdom.
Here is your January Wall Street’s Best Digest Top Picks issue 837.
Happy New Year to you all!
I hope your holidays were wonderful. I’m very hopeful for a much healthier New Year for all of us in 2021 and am also very thankful for the performance of the stock markets last year. The biggest winner was technology, with the Nasdaq returning a whopping 45%, followed by 18.4% at the S&P 500, and 9.7% at the Dow Jones Industrial Average.
And I’m thrilled to say, with this Top Picks issue and a calculation of 2020’s Top Picks, that our newsletter contributors really did hit it out of the park—with an average 180.19% return! Our Top 5 picks averaged 252.7%, with the #1 pick, Inovio Pharmaceuticals (INO)—chosen by Joseph Cotton of Cotton’s Technically Speaking—gaining 742.86%! Congratulations to them all!
And the crop of Top Pick recommendations for 2021 also look very attractive.
We begin with Growth stocks from the marijuana, electric vehicle charging, and space and air travel sectors. Our Financial choices include three banks and a jewelry company. In Healthcare, you’ll find a business of cell-based products, an insulin maker, COVID-related biotechs, and a couple of companies focusing on nervous system disorders.
Our Technology ideas come from the social media, search, travel, robotics, and artificial intelligence industries. The Real Estate Investment Trust section includes a marijuana REIT, as well as one that operates in the cell tower business. In High Yield, you’ll find a retail pharmacy and a tobacco company.
In Income, one of our contributors is focusing on Treasury bills instead of equities. And that conservative slant is also seen in our Resources and Energy section, where our advisors chose three gold companies, a pipeline business, and an electric utility. We’ve also included a few Low-Priced Stocks for you, coming from the energy, biotech, and lithium sectors.
Lastly, our Top Picks wrap up with a variety of Funds & ETFs in the income, cybersecurity, robotics/AI, and marijuana industries.
Our final recommendation this month is a non-Top Pick, an alternative energy company.
I’m looking forward to seeing how these Top Picks do this year, as well as bringing you lots more excellent recommendations from our more than 200 contributors. I look forward to hearing of your successes. Please reach out to me at nancy@financialfreedomfederation.com, with any questions and comments.
Happy New Year to you all!
I hope your holidays were wonderful. I’m very hopeful for a much healthier New Year for all of us in 2021 and am also very thankful for the performance of the stock markets last year. The biggest winner was technology, with the Nasdaq returning a whopping 45%, followed by 18.4% at the S&P 500, and 9.7% at the Dow Jones Industrial Average.
And I’m thrilled to say, with this Top Picks issue and a calculation of 2020’s Top Picks, that our newsletter contributors really did hit it out of the park—with an average 180.19% return! Our Top 5 picks averaged 252.7%, with the #1 pick, Inovio Pharmaceuticals (INO)—chosen by Joseph Cotton of Cotton’s Technically Speaking—gaining 742.86%! Congratulations to them all!
And the crop of Top Pick recommendations for 2021 also look very attractive.
We begin with Growth stocks from the marijuana, electric vehicle charging, and space and air travel sectors. Our Financial choices include three banks and a jewelry company. In Healthcare, you’ll find a business of cell-based products, an insulin maker, COVID-related biotechs, and a couple of companies focusing on nervous system disorders.
Our Technology ideas come from the social media, search, travel, robotics, and artificial intelligence industries. The Real Estate Investment Trust section includes a marijuana REIT, as well as one that operates in the cell tower business. In High Yield, you’ll find a retail pharmacy and a tobacco company.
In Income, one of our contributors is focusing on Treasury bills instead of equities. And that conservative slant is also seen in our Resources and Energy section, where our advisors chose three gold companies, a pipeline business, and an electric utility. We’ve also included a few Low-Priced Stocks for you, coming from the energy, biotech, and lithium sectors.
Lastly, our Top Picks wrap up with a variety of Funds & ETFs in the income, cybersecurity, robotics/AI, and marijuana industries.
Our final recommendation this month is a non-Top Pick, an alternative energy company.
I’m looking forward to seeing how these Top Picks do this year, as well as bringing you lots more excellent recommendations from our more than 200 contributors. I look forward to hearing of your successes. Please reach out to me at nancy@financialfreedomfederation.com, with any questions and comments.
Updates
Warren Buffett’s highly anticipated annual letter to shareholders was released on Saturday. In it, Buffett reaffirmed our conservative outlook on the market.
The stock market correction came and went rapidly in recent weeks! Granted, stocks are not done bouncing around yet, and a few sectors are lagging the broader market, including energy and healthcare.
Small caps paused this week to digest a few wild weeks. The S&P 600 Small Cap Index is essentially unchanged since I last wrote, which I think is a victory at this point.
Two of our stocks released earnings in the past week but there was no significant news. The economy, in general, is doing great, corporate profits are reaching record highs, and the European economy is improving. Although market reacted sharply to inflationary concerns, inflation is in line with Fed expectations.
The market has recovered well from its January–February slide, but after forming a V-shaped bounce, the major indexes have stalled out over the last few days. It’s likely that markets will need a while to catch their breath, and we don’t want to get ahead of them. In the Model Portfolio, while we are close to recommending new buys, we want to have the Cabot Tides at our back when we do so.
The market is certainly healthier, but it probably won’t go straight up from here. In fact, it’s more likely that sellers will see this bounce as an opportunity, and we’ll get another, probably smaller, leg down before the market starts a sustainable new uptrend.
Now that the stock market correction finally arrived, I want to sketch out what investors can expect in the near future.
What a difference a week makes. Last Friday, it seemed the market was in a death spiral and it was hard to make sense out of the volatility. This week has been downright placid, and all the major indexes are up nicely. Since last week’s update, the S&P 600 Small Cap Index is up by 5%.
The iShares EM Fund (EEM) gapped up to top its 25- and 50-day moving averages, which returns the Emerging Markets Timer to a positive reading. We are returning our half positions in two stocks and our full position in one stock to Buy ratings and initiating a new position.
I introduce a new stock to the prudent portfolio and am selling two stocks.
The 10-year yield has been quiet ahead of the announcement, trading sideways since Monday morning. That’s given utilities a bit of a reprieve, at least in the short term.
Now that the stock market correction has finally arrived, this weekly update is going to be a little bit different than normal. I’m not going to bother researching and reporting changes in earnings estimates, unless a company (a) just reported quarterly results within recent days and (b) the quarterly results significantly changed the future EPS projections.
Alerts
Earnings for this social media site were recently raised by 34%, and the company is forecasted to grow at an annual rate of 67.4% over the next five years.
Two stocks in the portfolio recently reported earnings.
Crista reports good earnings announcements in five portfolio stocks.
Analysts expect this semiconductor company to grow at a rate more than 29% this year.
Nine analysts have increased their earnings estimates for this consulting firm in the last 30 days.
The major indexes were mixed today, with the Dow up 29 points and the Nasdaq down 37 points.
This health insurer has also recently been recommended by Zacks, due to earnings and cash flow growth, as well as rising estimates.
Thus far, the 11 portfolio companies that delivered second-quarter results have all met or exceeded Wall Street’s consensus earnings estimates.
Analysts expect this casino company to spurt annual growth of 33.27% over the next five years.
This vehicle supplier beat analysts’ estimates by $.09 last quarter, and Wall Street expects it to grow at a rate of 27.5% this year.
Analysts expect this Indian online travel company to grow at an annual rate of 56.9% over the next five years.
Portfolios
Strategy
A few Cabot Options Trader subscribers have asked me about ways to protect gains in their portfolios, so I thought I would write to everyone with a couple of strategies using options to hedge your portfolio.
A subscriber recently asked me if I keep a journal of my trades. Many traders keep journals so they can look back at their trades and evaluate what they did right and what they did wrong.
Want to know how the big institutional investors use options? Here is an example of how one trader spent $132 million on three technology stocks.
Options trading has its own vernacular. To know how to do it, you need to know what every options term means. Here are some of the basics.
Our Cabot Top Ten Trader’s market timing system consists of two parts—one based on the action of three select, growth-oriented market indexes, and the other based on the action of the fast-moving stocks Cabot Top Ten features.